Share this article on:

Current World Literature

Current Opinion in Cardiology: January 2013 - Volume 28 - Issue 1 - p 80–84
doi: 10.1097/HCO.0b013e32835c1388
CURRENT WORLD LITERATURE: Bibliography

This bibliography is compiled by clinicians from the relevant journals scanned by this publication. It is based on the literature regularly pulled into our database from OvidSP (articles are generally added to the database about two and a half months after publication). In addition, the bibliography contains every paper annotated by reviewers; these references were obtained from a variety of bibliographic databases and published between the beginning of the review period and the time of going to press. The bibliography has been grouped into topics that relate to the reviews in this issue.

▪ Papers considered by the reviewers to be of special interest

▪▪ Papers considered by the reviewers to be of outstanding interest

The number in square brackets following a selected paper, e.g. [7], refers to its number in the annotated references of the corresponding review.

Back to Top | Article Outline

Arrhythmias

The importance of superior vena cava isolation in ablation strategy for atrial fibrillation

Review: (pp. 2–6)

▪▪. Chang HY, Lo LW, Lin YJ, et al. Long-term outcome of catheter ablation in patients with atrial fibrillation originating from the superior vena cava. J Cardiovasc Electrophysiol 2012; 23:955–961. [15]

▪. Chen G, Dong JZ, Liu XP, et al. Sinus node injury as a result of superior vena cava isolation during catheter ablation for atrial fibrillation and atrial flutter. PACE 2011; 34:163–170. [19]

Cohen LL, Stolerman M, Walsh C, Wasserman D, et al. Challenges of genetic testing in adolescents with cardiac arrhythmia syndromes. J Med Ethics 2012; 38:163–167.

Cordina RL, Celermajer DS, McGuire MA. Systemic venous anatomy in congenital heart disease: implications for electrophysiologic testing and catheter ablation. J Interv Card Electrophysiol 2012; 33:143–149.

Mulder AAW, Wijffels M, Wever EFD, Boersma LVA. Freedom from paroxysmal atrial fibrillation after successful pulmonary vein isolation with pulmonary vein ablation catheter-phased radiofrequency energy: 2-year follow-up and predictors of failure. Europace 2012; 14:818–825.

▪▪. Sicouri S, Blazek J, Belardinelli L, Antzelevitch C. Electrophysiological characteristics of canine superior vena cava sleeve preparations: effect of ranolazine. Circ Arrhythm Electrophysiol 2012; 5:371–379. [10]

Back to Top | Article Outline

Statin therapy and atrial fibrillation: systematic review and updated meta-analysis of published randomized controlled trials

Review: (pp. 7–18)

Augoustides JGT. Integrating Outcome Benefit Into Anesthetic Design: The Promise of Steroids and Statins. J Cardiothorac Vasc Anesth 2011; 25:880–884.

Bang CN, Greve AM, Boman K, Egstrup K, et al. Effect of lipid lowering on new-onset atrial fibrillation in patients with asymptomatic aortic stenosis: The Simvastatin and Ezetimibe in Aortic Stenosis (SEAS) study. Am Heart J 2012; 163:690–696.

Bhave PD, Auerbach A. Reply to the Editor-Statin use and postoperative atrial fibrillation after major noncardiac surgery. Heart Rhythm 2012; 9:E12–E13.

Bhave PD, Goldman LE, Vittinghoff E, Maselli JH, et al. Statin use and postoperative atrial fibrillation after major noncardiac surgery. Heart Rhythm 2012; 9:163–169.

Chopra V, Wesorick DH, Sussman JB, Greene T, et al. Effect of Perioperative Statins on Death, Myocardial Infarction, Atrial Fibrillation, and Length of Stay A Systematic Review and Meta-analysis. Arch Surg 2012; 147:181–189.

Dentali F, Gianni M, Squizzato A, Ageno W, et al. Use of statins and recurrence of atrial fibrillation after catheter ablation or electrical cardioversion. Thromb Haemost 2011; 106:363–370.

Giannakoulas G, Dimopoulos K, Yuksel S, Inuzuka R, et al. Atrial tachyarrhythmias late after Fontan operation are related to increase in mortality and hospitalization. Int J Cardiol 2012; 157:221–226.

Gibbons DD, Southerland EM, Hoover DB, Beaumont E, et al. Neuromodulation targets intrinsic cardiac neurons to attenuate neuronally mediated atrial arrhythmias. Am J Physiol-Regul Integr Comp Physiol 2012; 302:R357–R364.

Goette A. Neutral effects of statins to prevent atrial fibrillation recurrences after catheter ablation of atrial fibrillation: Should we bury upstream therapy for secondary prevention of atrial fibrillation? Heart Rhythm 2012; 9:179–180.

Gojkovic O, Aliot EM, Capucci A, Connolly SJ, et al. Celivarone in patients with an implantable cardioverter-defibrillator: Adjunctive therapy for the reduction of ventricular arrhythmia-triggered implantable cardioverter-defibrillator interventions. Heart Rhythm 2012; 9:217.

Goto S. Use of statins and recurrence of atrial fibrillation after catheter ablation or electrical cardioversion: An old question revisited. Thromb Haemost 2011; 106:187–188.

Khoo CW, Krishnamoorthy S, Lim HS, Lip GYH. Atrial fibrillation, arrhythmia burden and thrombogenesis. Int J Cardiol 2012; 157:318–323.

Khori V, Najafi SA, Alizadeh AM, Moheimani HR, et al. Protective role of simvastatin on isolated rabbit atrioventricular node during experimental atrial fibrillation model: role in rate control of ventricular beats. Naunyn-Schmiedebergs Arch Pharmacol 2012; 385:697–706.

Komatsu T, Tachibana H, Sato Y, Ozawa M, et al. Long-term Efficacy of Upstream Therapy With Lipophilic or Hydrophilic Statins on Antiarrhythmic Drugs in Patients With Paroxysmal Atrial Fibrillation Comparison Between Atorvastatin and Pravastatin. Int Heart J 2011; 52:359–365.

Lahoz C, Mostaza JM, Tranche S, Martin-Jadraque R, et al. Atherogenic dyslipidemia in patients with established coronary artery disease. Nutr Metab Carbiovasc Dis 2012; 22:103–108.

Laufs U, Adam O. Acute Effects of Statins. J Am Coll Cardiol 2012; 59:71–73.

Lemon SJ, Hatton KW, Ramaiah C, Mullett TW, et al. Evaluation of Atrial Arrhythmias Following Noncardiac Thoracic Surgery. Int Surg 2010; 95:205–209.

Liakopoulos OJ, Kuhn EW, Slottosch I, Wassmer G, et al. Preoperative statin therapy for patients undergoing cardiac surgery - art. no. CD008493. Cochrane Database Syst Rev 2012; 8493.

Matsuo S, Yamane T, Hioki M, Ito K, et al. Recurrent Atrial Arrhythmia in Patients with Atrial Fibrillation Following Pulmonary Vein Isolation. J Cardiovasc Electrophysiol 2011; 22:1080–1082.

Mulder AAW, Wijffels M, Wever EFD, Kelder JC, et al. Arrhythmia Detection after Atrial Fibrillation Ablation: Value of Incremental Monitoring Time. PACE-Pacing Clin Electrophysiol 2012; 35:164–169.

▪. Peña JM, MacFadyen J, Glynn RJ, Ridker PM. High-sensitivity C-reactive protein, statin therapy, and risks of atrial fibrillation: an exploratory analysis of the JUPITER trial. Eur Heart J 2012; 33:531–537. [30]

Petrac D, Radeljic V, Delic-Brkljacic D, Manola S, et al. Persistent Atrial Fibrillation is Associated with a Poor Prognosis in Patients with Atrioventricular Block and Dual-Chamber Pacemaker. PACE-Pacing Clin Electrophysiol 2012; 35:695–702.

Provost J, Vu THN, Legrand D, Okrasinski S, et al. Electromechanical wave imaging for arrhythmias. Phys Med Biol 2011; 56:L1–L11.

▪. Rahimi K, Emberson J, McGale P, et al. Effect of statins on atrial fibrillation: collaborative meta-analysis of published and unpublished evidence from randomised controlled trials. BMJ 2011; 342:d1250. doi: 10.1136/bmj.d1250. [42]

Rashba EJ, Estes NAM. Is There a Mechanistic Link Between Atrial Fibrillation and Vulnerability to Ventricular Arrhythmias? J Cardiovasc Electrophysiol 2011; 22:1253–1255.

Russo AM. The Impact of Dronedarone on Lone Atrial Fibrillation: Perhaps Not Such a ‘‘Benign’' Arrhythmia? J Cardiovasc Electrophysiol 2011; 22:777–780.

▪▪. Savelieva I, Kakouros N, Kourliouros A, Camm AJ. Upstream therapies for management of atrial fibrillation: review of clinical evidence and implications for European Society of Cardiology guidelines. Part I: Primary prevention. Europace 2011; 13:308–328. [04]

▪▪. Suleiman M, Koestler C, Lerman A, et al. Atorvastatin for prevention of atrial fibrillation recurrence following pulmonary vein isolation: a double-blind, placebo-controlled, randomized trial. Heart Rhythm 2012; 9:172–178. [32]

Suleiman M, Koestler C, Lerman A, Lopez-Jimenez F, et al. Atorvastatin for prevention of atrial fibrillation recurrence following pulmonary vein isolation: A double-blind, placebo-controlled, randomized trial. Heart Rhythm 2012; 9:172–178.

Tendolkar I, Enajat M, Zwiers MP, van Wingen G, et al. One-year cholesterol lowering treatment reduces medial temporal lobe atrophy and memory decline in stroke-free elderly with atrial fibrillation: evidence from a parallel group randomized trial. Int J Geriatr Psychiatr 2012; 27:49–58.

Wanahita N, Chen J, Bangalore S, Shah K, et al. The Effect of Statin Therapy on Ventricular Tachyarrhythmias: A Meta-Analysis. Am J Ther 2012; 19:16–23.

Wang ZS, Zhang Y, Gao M, Wang JR, et al. Stalin Therapy for the Prevention of Atrial Fibrillation: A Meta-analysis of Randomized Controlled Trials. Pharmacotherapy 2011; 31:1051–1062.

Workman AJ, Smith GL, Rankin AC. Mechanisms of termination and prevention of atrial fibrillation by drug therapy. Pharmacol Ther 2011; 131:221–241.

Xu Q, Guan YQ, Zhang D, Su GH. The effects of statin on atrial fibrillation: a meta-analysis of published data from randomized controlled trials. Curr Med Res Opin 2011; 27:1771–1779.

Back to Top | Article Outline

Unexplained sudden death, focussing on genetics and family phenotyping

Review: (pp. 19–25)

▪▪. Eckart RE, Shry EA, Burke AP, et al. Sudden death in young adults: an autopsy-based series of a population undergoing active surveillance. J Am Coll Cardiol 2011; 58:1254–1261. [06]

Leonard CE, Bilker WB, Newcomb C, Kimmel SE, et al. Additional data on citalopram and the risk of sudden cardiac death and ventricular arrhythmia. Pharmacoepidemiol Drug Saf 2012; 21:331–332.

Leonard CE, Bilker WB, Newcomb C, Kimmel SE, et al. Antidepressants and the risk of sudden cardiac death and ventricular arrhythmia. Pharmacoepidemiol Drug Saf 2011; 20:903–913.

Perry JC. Sudden Cardiac Death and Malignant Arrhythmias: The Scope of the Problem in Adult Congenital Heart Patients. Pediatr Cardiol 2012; 33:484–490.

▪. Raju H, Papadakis M, Govindan M, et al. Low prevalence of risk markers in cases of sudden death due to Brugada syndrome: relevance to risk stratification in Brugada syndrome. J Am Coll Cardiol 2011; 57:2340–2345. [17]

▪▪. Skinner JR, Crawford J, Smith W, et al. Prospective, population-based long QT molecular autopsy study of postmortem negative sudden death in 1 to 40 year olds. Heart Rhythm 2011; 8:412–419. [24]

▪▪. Tester DJ, Medeiros-Domingo A, Will ML, et al. Cardiac channel molecular autopsy: insights from 173 consecutive cases of autopsy-negative sudden unexplained death referred for postmortem genetic testing. Mayo Clin Proc 2012; 87:524–539. [20]

▪. Van der Werf C, Hofman N, Tan HL, et al. Diagnostic yield in sudden unexplained death and aborted cardiac arrest in the young: the experience of a tertiary referral center in The Netherlands. Heart Rhythm 2010; 7:1383–1389. [14]

Velagapudi P, Turagam M, Laurence T, Kocheril A. Cardiac Arrhythmias and Sudden Unexpected Death in Epilepsy (SUDEP). PACE-Pacing Clin Electrophysiol 2012; 35:363–370.

▪. Winkel BG, Larsen MK, Berge KE, et al. The prevalence of mutations in KCNQ1, KCNH2, and SCN5A in an unselected national cohort of young sudden unexplained death cases. J Cardiovasc Electrophysiol 2012. doi: 10.1111/j.1540-8167.2012.02371.x. [Epub ahead of print] [21]

Back to Top | Article Outline

How to ablate long-standing persistent atrial fibrillation?

Review: (pp. 26–35)

▪▪. Brooks AG, Stiles MK, Laborderie J, et al. Outcomes of long-standing persistent atrial fibrillation ablation: a systematic review. Heart Rhythm 2010; 7:835–846. [09]

▪▪. Di Biase L, Bai R, Mohanty P, et al. Atrial fibrillation triggers from the coronary sinus: comparison between isolation versus focal ablation. Heart Rhythm 2011; 8(Suppl 5):S78. [28]

▪▪. Di Biase L, Burkhardt JD, Mohanty P, et al. Left atrial appendage: an underrecognized trigger site of atrial fibrillation. Circulation 2010; 122:109–118. [10]

▪▪. Di Biase L, Burkhardt JD, Mohanty P, et al. Periprocedural stroke and management of major bleeding complications in patients undergoing catheter ablation of atrial fibrillation: the impact of periprocedural therapeutic international normalized ratio. Circulation 2010; 121:2550–2556. [13]

▪▪. Di Biase L, Conti S, Mohanty P, et al. General anesthesia reduces the prevalence of pulmonary vein reconnection during repeat ablation when compared with conscious sedation: results from a randomized study. Heart Rhythm 2011; 8:368–372. [20]

▪▪. Di Biase L, Santangeli P, Mohanty P, et al. Amiodarone increases the AF termination during ablation but reduces the long term success rate of patients undergoing ablation of long-standing persistent atrial fibrillation: preliminary results from the SPECULATE study. Heart Rhythm 2012; 9:S37. [17]

▪▪. Di Biase L, Santangeli P, Mohanty P, et al. Empirical left atrial appendage isolation improves the success rate of catheter ablation of long standing persistent atrial fibrillation after a single procedure: results from a prospective multicenter study. Heart Rhythm 2012; 9(Suppl 5):S126. [29]

▪. Elayi CS, Di Biase L, Barrett C, et al. Atrial fibrillation termination as a procedural endpoint during ablation in long-standing persistent atrial fibrillation. Heart Rhythm 2010; 7:1216–1223. [11]

▪▪. Hayward RM, Upadhyay GA, Mela T, et al. Pulmonary vein isolation with complex fractionated atrial electrogram ablation for paroxysmal and nonparoxysmal atrial fibrillation: a meta-analysis. Heart Rhythm 2011; 8:994–1000. [07]

Kulik A, Ruel M. Lipid-lowering therapy and coronary artery bypass graft surgery: what are the benefits? Curr Opin Cardiol 2011; 26:508–517.

▪▪. Lakkireddy D, Reddy YM, Di Biase L, et al. Feasibility and safety of dabigatran versus warfarin for periprocedural anticoagulation in patients undergoing radiofrequency ablation for atrial fibrillation: results from a multicenter prospective registry. J Am Coll Cardiol 2012; 59:1168–1174. [16]

▪▪. Li WJ, Bai YY, Zhang HY, et al. Additional ablation of complex fractionated atrial electrograms after pulmonary vein isolation in patients with atrial fibrillation: a meta-analysis. Circ Arrhythm Electrophysiol 2011; 4:143–148. [06]

Munoz MA, Kaur J, Vigmond EJ. Onset of atrial arrhythmias elicited by autonomic modulation of rabbit sinoatrial node activity: a modeling study. Am J Physiol-Heart Circul Physiol 2011; 301:H1974–H1983.

▪▪. Santangeli P, Di Biase L, Horton R, et al. Ablation of atrial fibrillation under therapeutic warfarin reduces periprocedural complications: evidence from a meta-analysis. Circ Arrhythm Electrophysiol 2012; 5:302–311. [14]

Smit MD, Van Gelder IC. New treatment options for atrial fibrillation: towards patient tailored therapy. Heart 2011; 97:1796–1802.

Back to Top | Article Outline

Epinephrine for cardiac arrest

Review: (pp. 36–42)

Almoustadi WA, Lee TWR, Klein J, Kumar K, et al. The effect of total spinal anesthesia on cardiac function in a large animal model of brain death. Can J Physiol Pharmacol 2012; 90:1287–1293.

▪. Burnett AM, Segal N, Salzman JG, et al. Potential negative effects of epinephrine on carotid blood flow and ETCO(2) during active compression-decompression CPR utilizing an impedance threshold device. Resuscitation 2012; 83:1021–1024. [15]

Daublander M, Kammerer PW, Willershausen B, Leckel M, et al. Clinical use of an epinephrine-reduced (1/400,000) articaine solution in short-time dental routine treatments-a multicenter study. Clin Oral Investig 2012; 16:1289–1295.

Davidson J, Zheng F, Tajima K, Barthel G, et al. Anaphylactic shock decreases cerebral blood flow more than what would be expected from severe arterial hypotension. Shock 2012; 38:429–435.

Enright K, Turner C, Roberts P, Cheng N, et al. Primary Cardiac Arrest Following Sport or Exertion in Children Presenting to an Emergency Department Chest Compressions and Early Defibrillation Can Save Lives, But Is Intravenous Epinephrine Always Appropriate? Pediatr Emerg Care 2012; 28:336–339.

▪▪. Hagihara A, Hasegawa M, Abe T, et al. Prehospital epinephrine use and survival among patients with out-of-hospital cardiac arrest. JAMA 2012; 307:1161–1168. [31]

▪. Hayashi Y, Iwami T, Kitamura T, et al. Impact of early intravenous epinephrine administration on outcomes following out-of-hospital cardiac arrest. Circ J 2012; 76:1639–1645. [33]

Imrich R, Nikolov NP, Bebris L, Alevizos I, et al. Adrenomedullary Response to Glucagon in Patients with Primary Sjogren's Syndrome. Cell Mol Neurobiol 2012; 32:903–906.

Isiordia-Espinoza MA, Orozco-Solis M, Tobias-Azua FJ, Mendez-Gutierrez EP. Submucous tramadol increases the anesthetic efficacy of mepivacaine with epinephrine in inferior alveolar nerve block. Br J Oral Maxillofac Surg 2012; 50:157–160.

▪▪. Jacobs IG, Finn JC, Jelinek GA, et al. Effect of adrenaline on survival in out-of-hospital cardiac arrest: a randomised double-blind placebo-controlled trial. Resuscitation 2011; 82:1138–1143. [26]

Litonius ES, Niiya T, Neuvonen PJ, Rosenberg PH. Intravenous Lipid Emulsion Only Minimally Influences Bupivacaine and Mepivacaine Distribution in Plasma and Does Not Enhance Recovery from Intoxication in Pigs. Anesth Analg 2012; 114:901–906.

Lord MS, Augoustides JGT. Perioperative Management of Pheochromocytoma: Focus on Magnesium, Clevidipine, and Vasopressin. J Cardiothorac Vasc Anesth 2012; 26:526–531.

Mauch J, Weiss M. Pediatric caudal anesthesia. Importance and aspects of safety concerns. Schmerz 2012; 26:443–453.

Mentzelopoulos SD, Zakynthinos SG, Siempos I, Malachias S, et al. Vasopressin for cardiac arrest: Meta-analysis of randomized controlled trials. Resuscitation 2012; 83: 32–39.

Nogami Y, Takase B, Kinoshita M, Shono S, et al. Liposome-encapsulated hemoglobin attenuates cardiac dysfunction and sympathetic activity during hypohemoglobinemic shock. Shock 2012; 38:159–164.

▪. Olasveengen TM, Wik L, Sunde K, Steen PA. Outcome when adrenaline (epinephrine) was actually given vs. not given – post hoc analysis of a randomized clinical trial. Resuscitation 2012; 83:327–332. [25]

Panda N, Verma RK, Panda NK. Efficacy and Safety of High-Concentration Adrenaline Wicks during Functional Endoscopic Sinus Surgery. J Otolaryngol-Head Neck Surg 2012; 41:131–137.

Patil PM, Patil SP. Is Clonidine an Adequate Alternative to Epinephrine as a Vasoconstrictor in Patients With Hypertension? J Oral Maxillofac Surg 2012; 70:257–262.

Toaimah FH, Al-Ansari K. Life-threatening Cardiac Arrhythmia after a Single Dose of Nebulized Epinephrine in Pediatric Emergency Department. J Trop Pediatr 2011; 57:497–499.

Toth-Heyn P, Cataldi L. Vasoactive Compounds in the Neonatal Period. Curr Med Chem 2012; 19:4633–4639.

Zhang H, Lau DH, Shlapakova IN, Zhao X, et al. Implantation of Sinoatrial Node Cells Into Canine Right Ventricle: Biological Pacing Appears Limited by the Substrate. Cell Transplant 2011; 20:1907–1914.

Back to Top | Article Outline

Ethical and legal perspective of implantable cardioverter defibrillator deactivation or implantable cardioverter defibrillator generator replacement in the elderly

Review: (pp. 43–49)

Clark AM, Jaarsma T, Strachan P, Davidson PM, et al. Effective communication and ethical consent in decisions related to ICDs. Nat Rev Cardiol 2011; 8:694–705.

Fields AV, Kirkpatrick JN. ETHICS OF THE HEART ethical and policy challenges in the treatment of advanced heart failure. Perspect Biol Med 2012; 55:71–80.

▪▪. Goldenberg I, Vyas AK, Hall WJ, et al. Risk stratification for primary implantation of a cardioverter-defibrillator in patients with ischemic left ventricular dysfunction. J Am Coll Cardiol 2008; 51:288–296. [28]

▪. Krahn AD, Lee DS, Birnie D, et al. Predictors of short-term complications after implantable cardioverter-defibrillator replacement: results from the Ontario ICD Database. Circ Arrhythm Electrophysiol 2011; 4:136–142. [15]

Kramer DB, Ottenberg AL, Gerhardson S, Mueller LA, et al. Just Because We Can Doesn't Mean We Should'': views of nurses on deactivation of pacemakers and implantable cardioverter-defibrillators. J Interv Card Electrophysiol 2011; 32:243–252.

▪. Lee DS, Tu JV, Austin PC, et al. Effect of cardiac and noncardiac conditions on survival after defibrillator implantation. J Am Coll Cardiol 2007; 49:2408–2415. [13]

Manaouil C, Fantoni S, Montpellier D, Tordjman E, et al. Practical questions around individual with a pacemaker or an implantable cardioverter defibrillator. Presse Med 2012; 41:736–744.

Mathews DJH. Deep brain stimulation, personal identity and policy. Int Rev Psych 2011; 23:486–492.

▪▪. Poole JE, Gleva MJ, Mela T, et al. Complication rates associated with pacemaker or implantable cardioverter-defibrillator generator replacements and upgrade procedures: results from the REPLACE registry. Circulation 2010; 122:1553–1561. [17]

Russo JE. Deactivation of ICDs at the End of Life: A Systematic Review of Clinical Practices and Provider and Patient Attitudes. Am J Nurs 2011; 111:26–37.

Tajouri TH, Ottenberg AL, Hayes DL, Mueller PS. The Use of Advance Directives among Patients with Implantable Cardioverter Defibrillators. PACE-Pacing Clin Electrophysiol 2012; 35:567–573.

Vinck I, De Laet C, Stroobandt S, Van Brabandt H. Legal and organizational aspects of remote cardiac monitoring: the example of implantable cardioverter defibrillators. Europace 2012; 14:1230–1235.

Whitlock SN, Goldberg IP, Singh JP. Is Pacemaker Deactivation at the End of Life Unique?: A Case Study and Ethical Analysis. J Palliat Med 2011; 14:1184–1188.

Back to Top | Article Outline

The importance of increased percentage of biventricular pacing to improve clinical outcomes in patients receiving cardiac resynchronization therapy

Review: (pp. 50–54)

▪▪. Ganesan A, Brooks A, Roberts-Thompson, et al. Role of AV nodal ablation incardiac resynchronization therapy in patients with coexistant atrial fibrillation and heart failure: a systematic review. J Am Coll Cardiol 2012; 59: 719–726. [12]

▪. Gasparini M, Galimberti P. AV junction ablation in heart failure patients with atrial fibrillation treated with cardiac resynchronization therapy: the picture is now clear!. J Am Coll Cardiol 2012; 59:727–729. [13]

▪▪. Hayes DL, Boehmer J, Day J. Cardiac resynchronization therapy and relationship of percentage biventricular pacing. Heart Rhythm 2011; 8:1469–1475. [07]

▪. Koplan BA, Kaplan AJ, Weiner S, et al. Heart failure decompensation and all-cause mortality in relation to percentage biventricular pacing in patients with heart failure: is a goal of 100% biventricular pacing necessary ? J Am Coll Cardiol 2009; 53:355–360. [08]

Kurita T, Noda T, Aiba T, Nakajima I, et al. Cardiac resynchronization therapy to prevent life-threatening arrhythmias in patients with congestive heart failure. J Electrocardiol 2011; 44:736–741.

▪. Martin DO, Lemke B, Birnie D, et al. Investigation of a Novel Algorithm for Synchronized Left-Ventricular Pacing and Ambulatory Optimization of Cardiac Resynchronization Therapy: Results of the Adaptive CRT Trial. Heart Rhythm 2012. [09]

Mond HG, Proclemer A. The 11th World Survey of Cardiac Pacing and Implantable Cardioverter-Defibrillators: Calendar Year 2009-A World Society of Arrhythmia's Project. PACE-Pacing Clin Electrophysiol 2011; 34:1013–1027.

Thijssen J, Borleffs CJW, Delgado V, van Rees JB, et al. Implantable Cardioverter-Defibrillator Patients Who Are Upgraded and Respond to Cardiac Resynchronization Therapy Have Less Ventricular Arrhythmias Compared With Nonresponders. J Am Coll Cardiol 2011; 58:2282–2289.

Back to Top | Article Outline

Sudden cardiac death in young athletes: what is the role of screening?

Review: (pp. 55–62)

AC C/AH A/ES C 2006 Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Death Kardiologiya 2011; 51:65–96.

Carro A. Evaluation of Cardiac Arrhythmia Among Athletes. Am J Med 2011; 124.

Dello Russo A, Pieroni M, Santangeli P, Bartoletti S, et al. Concealed cardiomyopathies in competitive athletes with ventricular arrhythmias and an apparently normal heart: role of cardiac electroanatomical mapping and biopsy. Heart Rhythm 2011; 8:1915–1922.

▪▪. Drezner JA, Asif IM, Owens DS, et al. Accuracy of ECG interpretation in competitive athletes: the impact of using standardised ECG criteria. Br J Sports Med 2012; 46:335–340. [54]

▪. Drezner JA, Fudge J, Harmon KG, et al. Warning symptoms and family history in children and young adults with sudden cardiac arrest. J Am Board Fam Med 2012; 25:408–415. [37]

▪▪. Eckart RE, Shry EA, Burke AP, et al. Department of Defense Cardiovascular Death Registry Group. Sudden death in young adults: an autopsy-based series of a population undergoing active surveillance. J Am Coll Cardiol 2011; 58:1254–1261. [14]

Giada F, Conte R, Pescatore V, Brugin E. Sports and arrhythmias. Minerva Med 2011; 102:239–247.

Gibbons DD, Southerland EM, Hoover DB, Beaumont E, et al. Neuromodulation targets intrinsic cardiac neurons to attenuate neuronally mediated atrial arrhythmias. Am J Physiol-Regul Integr Comp Physiol 2012; 302:R357–R364.

▪. Johnson JN, Ackerman MJ. Competitive sports participation in athletes with congenital long QT syndrome. JAMA 2012; 1–2. [56]

Lampert R. Evaluation and Management of Arrhythmia in the Athletic Patient. Prog Cardiovasc Dis 2012; 54:423–431.

Ludka O, Konecny T, Somers V. Sleep Apnea, Cardiac Arrhythmias, and Sudden Death. Tex Heart Inst J 2011; 38:340–343.

▪. Marek J, Bufalino V, Davis J, et al. Feasibility and findings of large-scale electrocardiographic screening in young adults: data from 32,561 subjects. Heart Rhythm 2011; 8:1555–1559. [44]

Miller LE, Hosick PA, Wrieden J, Hoyt E, et al. Evaluation of Arrhythmia Scoring Systems and Exercise-Induced Cardioprotection. Med Sci Sports Exerc 2012; 44: 435–441.

▪. Schoenbaum M, Denchev P, Vitiello B, Kaltman JR. Economic evaluation of strategies to reduce sudden cardiac death in young athletes. Pediatrics 2012; 130:e380–389. [48]

Tseng ZH, Secemsky EA, Dowdy D, Vittinghoff E, et al. Sudden Cardiac Death in Patients With Human Immunodeficiency Virus Infection. J Am Coll Cardiol 2012; 59:1891–1896.

Turagam MK, Velagapudi P, Szabo A, Visotcky A, et al. Survivors of sudden cardiac death with history of depression are not at significantly greater risk of recurrent arrhythmias and death. Int J Cardiol 2012; 157:445–446.

▪▪. Uberoi A, Stein R, Perez MV, et al. Interpretation of the electrocardiogram of young athletes. Circulation 2011; 124:746–757. [43]

Walker J, Calkins H, Nazarian S. Evaluation of Cardiac Arrhythmia Among Athletes Reply. Am J Med 2011 124.

Back to Top | Article Outline

Genetic testing in heritable cardiac arrhythmia syndromes: differentiating pathogenic mutations from background genetic noise

Review: (pp. 63–71)

▪▪. Ackerman MJ, Priori SG, Willems S, et al. HRS/EHRA expert consensus statement on the state of genetic testing for the channelopathies and cardiomyopathies: this document was developed as a partnership between the Heart Rhythm Society (HRS) and the European Heart Rhythm Association (EHRA). Heart Rhythm 2011; 8: 1308–1339. [07]

▪. Crotti L, Marcou CA, Tester DJ, et al. Spectrum and prevalence of mutations involving BrS1- through BrS12-susceptibility genes in a cohort of unrelated patients referred for Brugada syndrome genetic testing: implications for genetic testing. J Am Coll Cardiol 2012; 60:1410–1418. [70]

Cummings S, Priori G. Genetics of cardiac arrhythmias. Minerva Med 2011; 102:209–222.

▪▪. Gollob MH, Blier L, Brugada R, et al. Recommendations for the use of genetic testing in the clinical evaluation of inherited cardiac arrhythmias associated with sudden cardiac death: Canadian Cardiovascular Society/Canadian Heart Rhythm Society joint position paper. Can J Cardiol 2011; 27:232–245. [06]

Monteforte N, Napolitano C, Priori SG. Genetics and Arrhythmias: Diagnostic and Prognostic Applications. Rev Esp Cardiol 2012; 65:278–286.

▪. van der Werf C, Nederend I, Hofman N, et al. Familial evaluation in catecholaminergic polymorphic ventricular tachycardia: disease penetrance and expression in cardiac ryanodine receptor mutation-carrying relatives. Circ Arrhythm Electrophysiol 2012; 5:748–756. [61]

Back to Top | Article Outline

Electrical storm: definitions, clinical importance, and treatment

Review: (pp. 72–79)

▪. Ajijola OA, Lellouche N, Bourke T, et al. Bilateral cardiac sympathetic denervation for the management of electrical storm. J Am Coll Cardiol 2012; 59:91–92. [64]

Ajijola OA, Lellouche N, Bourke T, Tung R, et al. Bilateral Cardiac Sympathetic Denervation for the Management of Electrical Storm. J Am Coll Cardiol 2012; 59:91–92.

▪. Aliot EM, Stevenson WG, Almendral-Garrote JM, et al. EHRA/HRS Expert Consensus on Catheter Ablation of Ventricular Arrhythmias: developed in a partnership with the European Heart Rhythm Association (EHRA), a Registered Branch of the European Society of Cardiology (ESC), and the Heart Rhythm Society (HRS); in collaboration with the American College of Cardiology (ACC) and the American Heart Association (AHA). Heart Rhythm 2009; 6:886–933. [16]

Bogun F, Crawford T. Ablation for Ventricular Tachycardia Is More Always Better? How Much More Is Too Much? J Am Coll Cardiol 2012; 60:142–143.

Bun SS, Maury P, Giustetto C, Deharo JC. Electrical Storm in Short-QT Syndrome Successfully Treated with Isoproterenol. J Cardiovasc Electrophysiol 2012; 23:1028–1030.

▪. Carbucicchio C, Santamaria M, Trevisi N, et al. Catheter ablation for the treatment of electrical storm in patients with implantable cardioverter-defibrillators: short- and long-term outcomes in a prospective single-center study. Circulation 2008; 117:462–469. [53]

Chinushi M, Izumi D, Furushima H, Sato A, et al. Epicardial Scar in a Patient with no Apparent Heart Disease. PACE-Pacing Clin Electrophysiol 2012; 35:e136–e139.

de Oliveira FC, Feitosa GS, Ritt LEF. Use of beta-blockers for the treatment of cardiac arrest due to ventricular fibrillation/pulseless ventricular tachycardia: A systematic review. Resuscitation 2012; 83:674–683.

▪. Deneke T, Shin DI, Lawo T, et al. Catheter ablation of electrical storm in a collaborative hospital network. Am J Cardiol 2011; 108:233–239. [54]

Di Biase L, Santangeli P, Burkhardt DJ, Bai R, et al. Endo-Epicardial Homogenization of the Scar Versus Limited Substrate Ablation for the Treatment of Electrical Storms in Patients With Ischemic Cardiomyopathy. J Am Coll Cardiol 2012; 60:132–141.

Droogan C, Patel C, Yan GX, Kowey PR. Role of Antiarrhythmic Drugs: Frequent Implantable Cardioverter-Defibrillator Shocks, Risk of Proarrhythmia, and New Drug Therapy. Heart Fail Clin 2011; 7:195.

▪. Dunbar SB, Dougherty CM, Sears SF, et al. Educational and psychological interventions to improve outcomes for recipients of implantable cardioverter defibrillators and their families: a scientific statement From the American Heart Association. Circulation 2012; 126:2146–2172. [13]

▪. Frankel DS, Mountantonakis SE, Robinson MR, et al. Ventricular tachycardia ablation remains treatment of last resort in structural heart disease: argument for earlier intervention. J Cardiovasc Electrophysiol 2011; 22: 1123–1128. [57]

Furushima H, Chinushi M, Iijima K, Hasegawa K, et al. Is the coexistence of sustained ST-segment elevation and abnormal Q waves a risk factor for electrical storm in implanted cardioverter defibrillator patients with structural heart diseases? Europace 2012; 14:675–681.

Hottkowitz C, Ammann P, Kleger GR, Kunzli A, et al. Successful Management of a Case of Electrical Storm Due to Invasive Endocarditis - art. no. 245.e13. Can J Cardiol 2012; 28:E13.

Huang SH, Hsieh SC, Ko BS, Liu YB. Cardiac Involvement of Natural Killer/T-Cell Lymphoma Presenting With Electrical Storm After Cardioverter-Defibrillator Implantation. J Clin Oncol 2011; 29:E833–E836.

Hwang ES, Pak HN. Mid-Septal Hypertrophy and Apical Ballooning; Potential Mechanism of Ventricular Tachycardia Storm in Patients with Hypertrophic Cardiomyopathy. Yonsei Med J 2012; 53:221–223.

▪. Kozeluhova M, Peichl P, Cihak R, et al. Catheter ablation of electrical storm in patients with structural heart disease. Europace 2011; 13:109–113. [55]

▪. Kuck KH, Schaumann A, Eckardt L, et al. Catheter ablation of stable ventricular tachycardia before defibrillator implantation in patients with coronary heart disease (VTACH): a multicentre randomised controlled trial. Lancet 2010; 375:31–40. [51]

Mansour F, Khairy P. Electrical storm due to managed ventricular pacing. Heart Rhythm 2012; 9:842–843.

▪. Poole JE, Johnson GW, Hellkamp AS, et al. Prognostic importance of defibrillator shocks in patients with heart failure. N Engl J Med 2008; 359:1009–1017. [10]

Sternick EB, Piorkowski C, Hindricks G, Dagres N, et al. Electrical storm originating from a left ventricular epicardial scar in a patient with completely normal endocardial voltage. Heart Vessels 2011; 26:663–666.

Surber R, Prochnau D, Kuhnert H, Figulla HR. Incessant or recurrent ventricular tachycardia. Indications for emergency ablation. Med Klin-Intensivmed Notfallmed 2012; 107:362–367.

Tsuji Y. Electrical storm and calcium signaling: a review. J Electrocardiol 2011; 44:725–729.

Ukena C, Bauer A, Mahfoud F, Schreieck J, et al. Renal sympathetic denervation for treatment of electrical storm: first-in-man experience. Clin Res Cardiol 2012; 101:63–67.

Vaseghi M, Zhou W, Shi J, Ajijola OA, et al. Sympathetic innervation of the anterior left ventricular wall by the right and left stellate ganglia. Heart Rhythm 2012; 9:1303–1309.

Venkataraman G, Strickberger SA. The Role of Ventricular Tachycardia Ablation in the Reduction of Implantable Defibrillator Shocks. Heart Fail Clin 2011; 7:207.

Wissner E, Stevenson WG, Kuck KH. Catheter ablation of ventricular tachycardia in ischaemic and non-ischaemic cardiomyopathy: where are we today? A clinical review. Eur Heart J 2012; 33:1440.

Yamada T, Kay GN. Optimal ablation strategies for different types of ventricular tachycardias. Nat Rev Cardiol 2012; 9:512–525.

Back to Top | Article Outline

Predictors of pulmonary vein stenosis after atrial fibrillation ablation

Cohen LL, Stolerman M, Walsh C, Wasserman D, et al. Challenges of genetic testing in adolescents with cardiac arrhythmia syndromes. J Med Ethics 2012; 38:163– 167.

Khaykin Y, Oosthuizen R, Zarnett L, Essebag V, et al. Clinical Predictors of Arrhythmia Recurrences Following Pulmonary Vein Antrum Isolation for Atrial Fibrillation: Predicting Arrhythmia Recurrence Post-PVAI. J Cardiovasc Electrophysiol 2011; 22:1206–1214.

Matsuo S, Yamane T, Hioki M, Ito K, et al. Recurrent Atrial Arrhythmia in Patients with Atrial Fibrillation Following Pulmonary Vein Isolation. J Cardiovasc Electrophysiol 2011; 22:1080–1082.

Back to Top | Article Outline

The importance of atrioventricular nodal ablation in patients with atrial fibrillation receiving cardiac resynchronization therapy

Alhumaid F, Cheng A, Calkins H, Berger RD. Successful cryothermal ablation for Atrioventricular nodal reentry tachycardia after radiofrequency ablation failure. J Interv Card Electrophysiol 2012; 34:89–92.

Arana-Rueda E, Pedrote A, Sanchez-Brotons JA, Frutos-Lopez M, et al. Ablation of Atrioventricular Nodal Reentrant Tachycardia in a Patient with Tricuspid Atresia Guided by Electroanatomic Mapping. PACE-Pacing Clin Electrophysiol 2012; 35:E293–E295.

Chan NY, Mok NS, Choy CC, Lau CL, et al. Treatment of atrioventricular nodal re-entrant tachycardia by cryoablation with an 8-mm-tip catheter versus radiofrequency ablation. J Interv Card Electrophysiol 2012; 34:295–301.

Chatterjee NA, Upadhyay GA, Ellenbogen KA, Hayes DL, et al. Atrioventricular nodal ablation in atrial fibrillation: a meta-analysis of biventricular vs. right ventricular pacing mode. Eur J Heart Fail 2012; 14:661–667.

Chatterjee NA, Upadhyay GA, Ellenbogen KA, McAlister FA, et al. Atrioventricular Nodal Ablation in Atrial Fibrillation A Meta-Analysis and Systematic Review. Circ-Arrhythmia Electrophysiol 2012; 5:68.

Chen Z, Sunni N, A'Atty O, Ward DE, et al. Successful Ablation for Atrioventricular Nodal Reentrant Tachycardia in a Patient with Left Atrial Isomerism. PACE-Pacing Clin Electrophysiol 2012; 35:E291–E292.

Crosato M, Vaccari D, Calzolari V, Neri G, et al. Catheter ablation of atrioventricular nodal reentrant tachycardia in patients with a prolonged PR interval at sinus rhythm. J Cardiovasc Med 2012; 13:325–329.

Das S, Law IH, Von Bergen NH, Bradley DJ, et al. Cryoablation Therapy for Atrioventricular Nodal Reentrant Tachycardia in Children: A Multicenter Experience of Efficacy. Pediatr Cardiol 2012; 33:1147–1153.

De Sisti A, Tonet J, Amara W, Raguin D, et al. Correlations between long-term results after cryoablation for atrioventricular nodal reentry tachycardia and a residual jump associated or not with a single echo. Europace 2012; 14:261–266.

Femenia F, Arce M, Arrieta M, Palazzolo J, et al. Long-term results of slow pathway ablation in patients with atrioventricular nodal reentrant tachycardia: simple approach. J Electrocardiol 2012; 45:203–208.

Himmel F, Reppel M, Mortensen K, Schunkert H, et al. A Strategy to Achieve CRT Response in Permanent Atrial Fibrillation without Obligatory Atrioventricular Node Ablation. PACE-Pacing Clin Electrophysiol 2012; 35:943–947.

Jia-Feng L, Yue-Chun L, Peng-Lin Y, Ji-Fei T. Ablation of Atrioventricular Nodal Reentrant Tachycardia in a Patient with Reversal of Slow and Fast Pathways Inputs into the Atrioventricular Node. PACE-Pacing Clin Electrophysiol 2012; 35:e17–e19.

Jongbloed MRM, Kelder TP, Den Uijl DW, Bartelings MM, et al. Anatomical Perspective on Radiofrequency Ablation of AV Nodal Reentry Tachycardia after Mustard Correction for Transposition of the Great Arteries. PACE-Pacing Clin Electrophysiol 2012; 35:E287–E290.

Nagamoto Y, Inage T, Yoshida T, Takeuchi T, et al. Atrioventricular nodal ablation versus antiarrhythmic drugs after permanent pacemaker implantation for bradycardia-tachycardia syndrome. Heart Vessels 2012; 27:174–178.

Nakatani Y, Mizumaki K, Nishida K, Inoue H. Atrioventricular Node Ablation and Pacemaker Implantation for Recurrent Syncope in a Patient With Postural Tachycardia Syndrome (POTS). J Cardiovasc Electrophysiol 2011; 22:1284–1287.

Park KM, Rhee KS, Jin ES, Nam GB, et al. Effects of Slow Pathway Ablation on Fast Pathway Function in Patients With Atrioventricular Nodal Reentrant Tachycardia - Cryo- vs. Radiofrequency Ablation. Circ J 2012; 76:1091–1096.

Sairaku A, Nakano Y, Oda N, Makita Y, et al. Atrioventricular conduction properties in patients with prolonged pauses undergoing ablation of longstanding persistent atrial fibrillation: do pauses during atrial fibrillation matter? J Interv Card Electrophysiol 2012; 34:277–285.

Tonet J, De Sisti A, Restrepo NP, Raguin D, et al. Post-ablation prolongation of atrioventricular nodal refractory period is correlated with long-term success of cryoablation for atrioventricular nodal reentrant tachycardia in the case of the persistence of a residual jump. J Interv Card Electrophysiol 2012; 35:63–69.

Wang NC. Dual Atrioventricular Nodal Nonreentrant Tachycardia: A Systematic Review. PACE-Pacing Clin Electrophysiol 2011; 34:1671–1681.

Wang NC, Razak EA, Jain SK, Saba S. Isoproterenol Facilitation of Slow Pathway Ablation in Incessant Dual Atrioventricular Nodal Nonreentrant Tachycardia. PACE-Pacing Clin Electrophysiol 2012; 35:E31–E34.

Zhang YH, Mazgalev TN. Atrioventricular node functional remodeling induced by atrial fibrillation. Heart Rhythm 2012; 9:1419–1425.

Zhang YX, Lu CY, Xue Q, Li K, et al. Radiofrequency catheter ablation of atrioventricular nodal reentrant tachycardia guided by magnetic navigation system: a prospective randomized comparison with conventional procedure. Chin Med J 2012; 125:16–20.

Back to Top | Article Outline

New oral anticoagulation for the reduction of thromboembolic risk in patients with atrial fibrillation

Cervigon R, Moreno J, Reilly RB, Perez-Villacastin J, et al. Quantification of anaesthetic effects on atrial fibrillation rate by partial least-squares. Physiol Meas 2012; 33:1757–1768.

Chang HY, Lo LW, Lin YJ, Chang SL, et al. Long-Term Outcome of Catheter Ablation in Patients with Atrial Fibrillation Originating from the Superior Vena Cava. J Cardiovasc Electrophysiol 2012; 23:955–961.

Ciaccio EJ, Biviano AB, Whang W, Gambhir A, et al. Spectral Profiles of Complex Fractionated Atrial Electrograms Are Different in Longstanding and Acute Onset Atrial Fibrillation Atrial Electrogram Spectra. J Cardiovasc Electrophysiol 2012; 23:971–979.

Kaseno K, Naito S, Nakamura K, Sakamoto T, et al. Efficacy and Safety of Periprocedural Dabigatran in Patients Undergoing Catheter Ablation of Atrial Fibrillation. Circ J 2012; 76:2337–2342.

Liu L, Lee J, Fu GQ, Liu XT, et al. Activation of Peripheral Blood CD3(+) T-lymphocytes in Patients With Atrial Fibrillation. Int Heart J 2012; 53:221–224.

Liu SX, Zhang Y, Zhang XW. Impact of Image Integration on Catheter Ablation for Atrial Fibrillation Using Three-Dimensional Electroanatomic Mapping: A Meta-Analysis. PACE-Pacing Clin Electrophysiol 2012; 35:1242–1247.

Matsuo S, Yamane T, Date T, Tokutake KI, et al. Substrate Modification by Pulmonary Vein Isolation and Left Atrial Linear Ablation in Patients with Persistent Atrial Fibrillation: Its Impact on Complex-Fractionated Atrial Electrograms. J Cardiovasc Electrophysiol 2012; 23:962–970.

Miyazaki S, Kuwahara T, Takahashi A. Impact of the Preprocedural Frequency of Paroxysmal Atrial Fibrillation on the Clinical Outcome after Catheter Ablation. PACE-Pacing Clin Electrophysiol 2012; 35:1236–1241.

Mulder BA, van Veldhuisen DJ, Crijns H, Bohm M, et al. Effect of nebivolol on outcome in elderly patients with heart failure and atrial fibrillation: insights from SENIORS. Eur J Heart Fail 2012; 14:1171–1178.

Rich MW. Atrial Fibrillation in Long Term Care. J Am Med Dir Assoc 2012; 13:688–691.

Rosenman MB, Baker L, Jing YH, Makenbaeva D, et al. Why is warfarin underused for stroke prevention in atrial fibrillation? A detailed review of electronic medical records. Curr Med Res Opin 2012; 28:1407–1414.

Schoen T, Pradhan AD, Albert CM, Conen D. Type 2 Diabetes Mellitus and Risk of Incident Atrial Fibrillation in Women. J Am Coll Cardiol 2012; 60:1421–1428.

Shi AW, Chen ML, Yang B, Cao KJ, et al. A Morphological Study of the Left Atrial Appendage in Chinese Patients with Atrial Fibrillation. J Int Med Res 2012; 40:1560–1567.

Surges R, Moskau S, Viebahn B, Schoene-Bake JC, et al. Prolonged atrial fibrillation following generalized tonic-clonic seizures. Seizure 2012; 21:643–645.

Suzuki H, Takeishi Y. Inducibility of Atrial Fibrillation Caused by Acute Increase of Atrial Pressure in Rat Diseased Heart With Chronic Atrial Dilation. Int Heart J 2012; 53:257–260.

Back to Top | Article Outline

Catheter ablation of atrial fibrillation in patients with heart failure

Ammar S, Hessling G, Reents T, Fichtner S, et al. Arrhythmia Type After Persistent Atrial Fibrillation Ablation Predicts Success of the Repeat Procedure. Circ-Arrhythmia Electrophysiol 2011; 4:609–614.

Cho HJ, On YK, Bang OY, Kim JW, et al. Development and Comparison of a Warfarin-Dosing Algorithm for Korean Patients With Atrial Fibrillation. Clin Ther 2011; 33:1371–1380.

Dixit S, Marchlinski FE. Role of Continuous Monitoring for Optimizing Management Strategies in Patients With Early Arrhythmia Recurrences After Atrial Fibrillation Ablation. Circ-Arrhythmia Electrophysiol 2011; 4:791–793.

Gibbons DD, Southerland EM, Hoover DB, Beaumont E, et al. Neuromodulation targets intrinsic cardiac neurons to attenuate neuronally mediated atrial arrhythmias. Am J Physiol-Regul Integr Comp Physiol 2012; 302:R357–R364.

Goette A. Neutral effects of statins to prevent atrial fibrillation recurrences after catheter ablation of atrial fibrillation: Should we bury upstream therapy for secondary prevention of atrial fibrillation? Heart Rhythm 2012; 9:179–180.

Gojkovic O, Aliot EM, Capucci A, Connolly SJ, et al. Celivarone in patients with an implantable cardioverter-defibrillator: Adjunctive therapy for the reduction of ventricular arrhythmia-triggered implantable cardioverter-defibrillator interventions. Heart Rhythm 2012; 9:217.

Kazemian P, Gollob MH, Pantano A, Oudit GY. A Novel Mutation in the RYR2 Gene Leading to Catecholaminergic Polymorphic Ventricular Tachycardia and Paroxysmal Atrial Fibrillation: Dose-Dependent Arrhythmia-Event Suppression by beta-Blocker Therapy - art. no. 870.e7. Can J Cardiol 2011; 27:E7.

Lellouche N, Sebag FA, Elbaz N, Hassine M, et al. Acute pericardial effusion following atrial fibrillation ablation: Characteristics and relationship with arrhythmia recurrences. Arch Cardiovasc Dis 2011; 104:450–457.

Mountantonakis S, Deo R. Biomarkers in Atrial Fibrillation, Ventricular Arrhythmias, and Sudden Cardiac Death. Cardiovasc Ther 2012; 30:e74–e80.

Mulder AAW, Wijffels M, Wever EFD, Boersma LVA. Freedom from paroxysmal atrial fibrillation after successful pulmonary vein isolation with pulmonary vein ablation catheter-phased radiofrequency energy: 2-year follow-up and predictors of failure. Europace 2012; 14:818–825.

Potpara TS, Stankovic GR, Beleslin BD, Polovina MM, et al. A 12-Year Follow-up Study of Patients With Newly Diagnosed Lone Atrial Fibrillation Implications of Arrhythmia Progression on Prognosis: The Belgrade Atrial Fibrillation Study. Chest 2012; 141:339–347.

Rordorf R, Savastano S, Gandolfi E, Vicentini A, et al. Pharmacological therapy following catheter ablation of atrial fibrillation. J Cardiovasc Med 2012; 13:9–15.

Russo AM. The Impact of Dronedarone on Lone Atrial Fibrillation: Perhaps Not Such a ‘‘Benign’' Arrhythmia? J Cardiovasc Electrophysiol 2011; 22:777–780.

Ye L, Zhu W, Backx PH, Cortez MA, et al. Arrhythmia and sudden death associated with elevated cardiac chloride channel activity. J Cell Mol Med 2011; 15:2307–2316.

Back to Top | Article Outline

Should patients with coronary artery disease receive Dabigatran?

Aizman A, Abbott E, Rojas L. Strategies for the prophylaxis of thromboembolic disease among medical patients. Rev Medica Chile 2011; 139:1210–1217.

Arsenault KA, Hirsh J, Whitlock RP, Eikelboom JW. Direct thrombin inhibitors in cardiovascular disease. Nat Rev Cardiol 2012; 9:402–414.

De Caterina R, Husted S, Wallentin L, Andreotti F, et al. New Oral Anticoagulants in Atrial Fibrillation and Acute Coronary Syndromes ESC Working Group on Thrombosis-Task Force on Anticoagulants in Heart Disease Position Paper. J Am Coll Cardiol 2012; 59:1413–1425.

Dumkow LE, Voss JR, Peters M, Jennings DL. Reversal of dabigatran-induced bleeding with a prothrombin complex concentrate and fresh frozen plasma. Am J Health-Syst Pharm 2012; 69:1646–1650.

Hohnloser SH, Oldgren J, Yang S, Wallentin L, et al. Myocardial Ischemic Events in Patients With Atrial Fibrillation Treated With Dabigatran or Warfarin in the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) Trial. Circulation 2012; 125:669–676.

Iyer V, Singh HS, Reiffel JA. Dabigatran: Comparison to Warfarin, Pathway to Approval, and Practical Guidelines for Use. J Cardiovasc Pharmacol Ther 2012; 17:237–247.

Kennedy B, Gargoum FS, Kennedy L, Khan F, et al. Emerging Anticoagulants. Curr Med Chem 2012; 19:3388–3416.

Kernan L, Ito S, Shirazi F, Boesen K. Fatal gastrointestinal hemorrhage after a single dose of dabigatran. Clin Toxicol 2012; 50:571–573.

Lambourne MD, Eltringham-Smith LJ, Gataiance S, Arnold DM, et al. Prothrombin complex concentrates reduce blood loss in murine coagulopathy induced by warfarin, but not in that induced by dabigatran etexilate. J Thromb Haemost 2012; 10:1830–1840.

McKeage K. Dabigatran Etexilate A Pharmacoeconomic Review of its Use in the Prevention of Stroke and Systemic Embolism in Patients with Atrial Fibrillation. Pharmacoeconomics 2012; 30:841–855.

Morales-Vidal S, Schneck MJ, Flaster M, Biller J. Direct thrombin inhibitors and factor Xa inhibitors in patients with cerebrovascular disease. Expert Rev Neurother 2012; 12: 179–190.

Patel PA, Ramakrishna H, Andritsos M, Wyckoff T, et al. The Year in Cardiothoracic and Vascular Anesthesia: Selected Highlights From 2011. J Cardiothorac Vasc Anesth 2012; 26:3–10.

Pinto DJP, Qiao JX, Knabb RM. The emergence of factor Xa inhibitors for the treatment of cardiovascular diseases: a patent review. Expert Opin Ther Patents 2012; 22:645–661.

Redondo S, Martinez MP, Ramajo M, Navarro-Dorado J, et al. Pharmacological basis and clinical evidence of dabigatran therapy - art. no. 53. J Hematol Oncol 2011; 4:21.

Van de Werf F, Brueckmann M, Connolly SJ, Friedman J, et al. A comparison of dabigatran etexilate with warfarin in patients with mechanical heart valves: The Randomized, phase II study to Evaluate the sAfety and pharmacokinetics of oraL dablGatran etexilate in patients after heart valve replacemeNt (RE-ALIGN) - art. no. 937.e1. Am Heart J 2012; 163:931.

© 2013 Lippincott Williams & Wilkins, Inc.